Home | About NDA | NDA Services | NDA Advisory Boards | Contact NDA

Welcome to NDA - Europe’s leading regulatory affairs consultancy

NDA provides clients with a unique insight into EU regulatory thinking and the best possible expert guidance and support to optimise the time to the European market.

NDA’s mission is to ensure that patients get access to good medicines without unnecessary delay. NDA has successfully delivered on this promise for over ten years. In 2009 NDA was involved in more than 30% of all positive opinions under the EU Centralised Procedure!

The experience and knowledge of NDA's regulatory consultants are unmatched in Europe.

EMA Calendar

Online Brochure

Client Feedback

NDA's Brian Edwards to feature in two pharmacovigilance events

Dr Brian Edwards is a key speaker at the 7th Annual Pharmacovigilance on 30th – 31st January, Thistle City Barbican, London, UK. Dr Edwards is also on the Programme Committee at the 6th European Forum for Qualified Person for Pharmacovigilance (QPPV) on Apr 24th - 26th, Hilton London Docklands Riverside Hotel.More of this story >

NDA launches new Advisory Board and joint HTA/RA service

Following the succesful delivery of top level regulatory advice since 2002, NDA is now complementing its Regulatory Advisory Board with the addition of the NDA HTA Advisory Services. The new addition allows NDA to provide a unique advisory service, combining Europe's top level regulatory and HTA expertise to deliver joint advice.More of this story >

Graham Higson to lead NDA Advisory Board

GE Healthcare and ex AstraZeneca Head of Global Regulatory Affairs, Graham Higson, will join NDA Group in January 2012 to lead its unique-in-the industry Regulatory Affairs and HTA Advisory Board.More of this story >

The impact of the Paediatric Regulation on existing medicinal products

This article, written by NDAs Jill Challis, reviews the impact of the Regulation over the last five years on improving the likelihood for safer and more effective use of existing medicines in children.More of this story >

Making a success of new drug development

Wasting $60 billion on failed drug development programmes is unacceptable. But just how does the industry improve its strategy in getting new drugs to market quicker? NDA's CEO, Dr Lars-Helge Strömquist, comments on the state of the industry.More of this story >

Assessing whether your Rx product is ready for a switch to OTC in the EU

Pharmaceutical companies have many factors to consider in deciding whether a switch to over the counter is the right strategy for their products. NDA's Rosalind Cox recommends a structured approach.More of this story >

The NDA Group is an independent consulting organization delivering services within outcome oriented drug development focused on the strategic and operational aspects of regulatory affairs. NDA provides assistance to both the Pharmaceutical Industry as well as Regulatory Agencies. The ultimate objective of NDA is to help to develop better medicines that reach the patient without unnecessary delay. NDA achieves this objective by critically reviewing client project development plans with the aim that they are optimized to meet the needs of regulatory authorities and then to help to implement those strategies. NDA strives to bridge the communication gap between "the regulators" and "the regulated" to the benefit of patients.

The NDA Group provides services within several different areas such as regulatory affairs, pharmacovigilance and patient safety and quality assurance. NDA's regulatory consultants have extensive knowledge and experience working with traditional pharmaceuticals, biopharma, medical devices and production processes within the pharmaceutical industry.

The NDA Group also provides expert and strategic advice on development and regulatory strategies and assists the pharmaceutical industry with qualified training.